Inhaled drug delivery is also termed as pulmonary drug delivery. It is the inhalation of drug formulation through the mouth and further deposition of the inhaled pharmacological agent in lower airways is the main purpose of this drug delivery rate. The inhalation therapies involved the use of leaves from plants, vapours from aromatic plants, balsams and myhrr. Delivery of drugs directly to the site of action reduces the dose needed to produce a pharmacological effect.
In recent years, the possibility of utilizing the pulmonary route for the systemic delivery of peptides and other molecules that are not absorbed through the gastrointestinal tract has also been explored.
Title : Nanomaterial-mediated systemically-administered m-rna-based Gene therapy directed exclusively to cancer, resulting in eradication of implanted orthotopic tumors with no side effects
A C Matin, Stanford University, United States
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Qualitative and quantitative measures of drugs’ placenta permeability - a chromatographic and computational approach
Anna Weronika Sobańska, Medical University of Lodz, Poland
Title : The signification of the blood-brain barrier to the transfer of essential and toxic mineral elements
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : HDAC inhibitors with non-hydroxamate warhead
Franz Josef Meyer Almes, University of Applied Sciences, Germany
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey
Title : Digital health: Education in clinical pharmacy and implementation in practice
Aysu selcuk, Ankara University, Turkey
Title : Pharmacovigilance – Important, current trends, challenges and opportunities
Gurpreet Singh, Freyr Lifesciences Limited, United Kingdom